The Jerusalem Mental Health Center, Jerusalem, Israel 91060.
Compr Psychiatry. 2010 Jan-Feb;51(1):37-41. doi: 10.1016/j.comppsych.2009.03.008. Epub 2009 May 6.
The influence of cannabis abuse on the severity of existing psychotic and affective symptoms is still unclear. Among 470 consecutively admitted psychotic or affective patients, 54 active (in the previous month) cannabis abusers were detected via urine tests (Sure Step TM kits; Applied Biotech Inc, San Diego, Calif) and Structured Clinical Interview for DSM-IV (SCID- IV) questionnaire. In 24 cases, substances other than cannabis were abused; 392 patients were nonabusers. All patients were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria. The following rating scales were used: Hamilton Depression Rating Scale (HAM-D-21), Positive and Negative Syndrome Scale (PANSS), and Young Mania Rating Scale (YMRS). Cannabis abusers (n = 54) were significantly younger and more frequently males than nonuser patients. In this group, there were more schizophrenic patients and fewer affective and anxiety patients (chi(2) = 11.76; P < .01). The double-diagnosed patients had more prominent psychotic symptoms than the nonusers (n = 392)-PANSS positive: 19.056 +/- 8.30 vs 16.128 +/- 8.031 (P < .02; t(446) = 2.510). The difference was statistically significant for hallucinatory behavior, excitement, grandiosity, and hostility. General PANSS scale rate of abusers was lower: 33.012 +/- 9.317 vs 37.3575 +/- 11.196 (P < .01; t = 2.727), especially for depression, anxiety, somatic concern, guilt feelings, tension, motor retardation, and volition disturbances. Rates of PANSS negative scale of abusers and nonusers were not significantly different (13.815 +/- 6.868 vs 14.983 +/- 6.446) except for lower rates of social withdrawal and stereotyped thinking for abusers. No significant difference in general level of manic symptoms (YMRS) between abusers and nonusers was observed (6.778 +/- 10.826 vs 4.910 +/- 7.754), but severity of thought/language disturbances and poor insight was found significantly higher in the abusers. Cannabis abusers are obviously less depressive (HAM-D): 5.944 +/- 10.291 vs 12.896 +/- 13.946 (P < .0005, t = 3.535). Such differences were observed in the high number of the subscales. Abusers' rates were higher (although not significantly) for paranoid symptoms and general somatic symptoms. Cannabis possibly produces some antidepressive and anxiolytic effect on psychotic and affective inpatients. The "price" of this effect is often an exacerbation of psychotic and some manic symptoms.
大麻滥用对现有精神病和情感症状严重程度的影响仍不清楚。在连续收治的 470 名精神病或情感患者中,通过尿液检测(Sure Step TM 试剂盒;Applied Biotech Inc.,加利福尼亚圣地亚哥)和 DSM-IV 结构临床访谈(SCID- IV)问卷发现 54 名活跃(上个月)大麻滥用者。在 24 例中,滥用了大麻以外的物质;392 名患者是非滥用者。所有患者均根据《精神障碍诊断与统计手册》第四版标准进行诊断。使用了以下评定量表:汉密尔顿抑郁量表(HAM-D-21)、阳性和阴性综合征量表(PANSS)和 Young 躁狂评定量表(YMRS)。大麻滥用者(n=54)明显比非使用者年轻,且更多为男性。在该组中,精神分裂症患者更多,情感和焦虑症患者更少(chi(2)=11.76;P<.01)。与非使用者相比,双诊断患者的精神病症状更为突出(n=392)-PANSS 阳性:19.056 +/- 8.30 与 16.128 +/- 8.031(P<.02;t(446)=2.510)。在幻觉行为、兴奋、夸大和敌意方面,差异具有统计学意义。使用者的一般 PANSS 量表评分较低:33.012 +/- 9.317 与 37.3575 +/- 11.196(P<.01;t=2.727),尤其是抑郁、焦虑、躯体关注、内疚感、紧张、运动迟缓以及意志障碍。使用者和非使用者的 PANSS 阴性量表评分无显著差异(13.815 +/- 6.868 与 14.983 +/- 6.446),但使用者的社交退缩和刻板思维发生率较低。未观察到使用者和非使用者的一般躁狂症状严重程度(YMRS)有显著差异(6.778 +/- 10.826 与 4.910 +/- 7.754),但发现使用者的思维/语言障碍和洞察力缺失更为严重。大麻滥用者明显较轻抑郁(HAM-D):5.944 +/- 10.291 与 12.896 +/- 13.946(P<.0005,t=3.535)。在许多亚量表中都观察到了这种差异。使用者的偏执症状和一般躯体症状评分较高(尽管无统计学意义)。大麻可能对精神病和情感住院患者产生一些抗抑郁和抗焦虑作用。这种作用的“代价”通常是精神病和一些躁狂症状的加重。